Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

172.50USD
23 Jun 2017
Change (% chg)

$-1.32 (-0.76%)
Prev Close
$173.82
Open
$173.24
Day's High
$174.13
Day's Low
$170.96
Volume
14,368,474
Avg. Vol
3,754,755
52-wk High
$184.21
52-wk Low
$133.64

AMGN.O

Chart for AMGN.O

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.37
Market Cap(Mil.): $126,856.40
Shares Outstanding(Mil.): 735.40
Dividend: 1.15
Yield (%): 2.67

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.34 239.63 19.01
EPS (TTM): 10.55 -- --
ROI: 11.79 -8.17 -5.03
ROE: 26.61 -11.48 -4.28

BRIEF-Amgen receives positive CHMP opinion to expand use of mimpara

* Amgen receives positive CHMP opinion to expand use of mimpara (cinacalcet) for the treatment of secondary hyperparathyroidism in certain children with end-stage renal disease on dialysis

Jun 23 2017

BRIEF-Amgen's multiple Myeloma treatment in combination with Dexamethasone, receives NICE recommendation for use at first relapse

* Amgen's multiple Myeloma treatment, Kyprolis® (Carfilzomib), in combination with Dexamethasone, receives NICE recommendation for use at first relapse

Jun 12 2017

UPDATE 4-U.S. Supreme Court speeds copycat biologic drugs to market

WASHINGTON, June 12 The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies.

Jun 12 2017

FDA rejects Coherus's biosimilar for Neulasta, shares plunge

Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA)30 declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients.

Jun 12 2017

RPT-UPDATE 3-FDA rejects Coherus's biosimilar for Neulasta, shares plunge

June 12 Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its biosimilar copy of Amgen Inc's blockbuster treatment, Neulasta, which is used to fight infections in cancer patients.

Jun 12 2017

FDA rejects Coherus's biosimilar for Neulasta, shares plunge

* Coherus shares tumble 30 pct, Amgen up slightly (Adds background, details from conference call; updates shares)

Jun 12 2017

FDA rejects Coherus' biosimilar for Amgen's Neulasta

Coherus BioSciences Inc said on Monday the U.S. Food and Drug Administration (FDA) denied the approval of its biosimilar for Amgen Inc's blockbuster treatment, Neulasta, which fights infections in cancer patients.

Jun 12 2017

BRIEF-Amgen, Allergan announce FDA advisory committee meeting to review ABP 215

* Amgen and Allergan announce fda advisory committee meeting to review ABP 215, a biosimilar candidate to bevacizumab

Jun 07 2017

Regeneron, Sanofi urge court to reverse ban on cholesterol drug

A federal appeals court hinted on Tuesday it may let Sanofi AG and Regeneron Pharmaceuticals Inc sell a cholesterol drug Amgen Inc has been trying to block on patent infringement grounds, according to lawyers and analysts who attended oral arguments in the case.

Jun 06 2017

Regeneron, Sanofi urge court to reverse ban on cholesterol drug

June 6 A federal appeals court hinted on Tuesday it may let Sanofi AG and Regeneron Pharmaceuticals Inc sell a cholesterol drug Amgen Inc has been trying to block on patent infringement grounds, according to lawyers and analysts who attended oral arguments in the case.

Jun 06 2017

More From Around the Web

Earnings vs. Estimates